Credit: Pixabay/CC0 Public Domain In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those seen in clinical trials, according to results published in Blood. Of 236 patients who received cilta-cel infusions at 16 U.S. medical centers in 2022,...
Tag: <span>cilta-cel</span>
Post
FDA approves cilta-cel for multiple myeloma
A laboratory technician carries a cryogenic container of blood to be treated before genetically modifying a patient’s immune cells in the laboratory. March 8, 2019, at a production laboratory unit of the Paoli-Calmettes Institute in France. GERARD JULIEN/AFP via Getty Images On February 28, 2022, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (cilta-cel)...